DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Mapatumumab is an investigational drug.
There have been 5 clinical trials for Mapatumumab. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2007.
The most common disease conditions in clinical trials are Carcinoma, Hepatocellular, Carcinoma, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Human Genome Sciences Inc., Human Genome Sciences Inc., a GSK Company, and GlaxoSmithKline.
Recent Clinical Trials for Mapatumumab
|Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma||GlaxoSmithKline||Phase 2|
|Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma||Human Genome Sciences Inc., a GSK Company||Phase 2|
|Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer||Human Genome Sciences Inc.||Phase 1/Phase 2|